WO2001015666A1 - Mixed micellar pharmaceutical delivery system and method of preparation - Google Patents
Mixed micellar pharmaceutical delivery system and method of preparation Download PDFInfo
- Publication number
- WO2001015666A1 WO2001015666A1 PCT/CA2000/001019 CA0001019W WO0115666A1 WO 2001015666 A1 WO2001015666 A1 WO 2001015666A1 CA 0001019 W CA0001019 W CA 0001019W WO 0115666 A1 WO0115666 A1 WO 0115666A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formulation
- concentration
- group
- acid
- lecithin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to an improved delivery system for the administration of large-molecule pharmaceuticals, e.g. peptidic drugs, vaccines and hormones.
- large-molecule pharmaceuticals e.g. peptidic drugs, vaccines and hormones.
- pharmaceuticals which may be administered through the oral and nasal membranes.
- the oral routes have received far more attention than has the other routes.
- the sublingual mucosa includes the membrane of ventral surface of the tongue and the floor of the mouth whereas the buccal mucosa constitutes the lining of the cheek.
- the sublingual mucosa is relatively permeable thus giving rapid absorption and acceptable bioavailability of many drugs. Further, the sublingual mucosa is convenient, acceptable and easily accessible.
- This route has been investigated clinically for the delivery of a substantial number of drugs.
- the ability of molecules to permeate through the oral mucosa appears to be related to molecular size, lipid solubility and peptide protein ionization. Small molecules, less than 1000 daltons appear to cross mucosa rapidly. As molecular size increases, the permeability decreases rapidly. Lipid soluble compounds are more permeable than non-lipid soluble molecules. Maximum absorption occurs when molecules are un-ionized or neutral in electrical charges. Therefore charged molecules present the biggest challenges to absorption through the oral mucosae.
- Enhancers may be characterized as chelators, bile salts, fatty acids, synthetic hydrophillic and hydrophobic compounds, and biodegradable polymeric compounds. Various mechanisms of action of enhancers have been proposed.
- This system allows opening of the paracellular junctions (tight junctions) in oral as well - A - as in GI tract by gl motility movement with high degree of protease activity preserved and protecting molecules from premature degradation in the hostile acidic and proteolytic GI environment.
- the mixed micelles encapsulate molecules with high degree of efficiency (>90% encapsulation). These mixed micelles are extremely small in the size (1 nm to 10 nm), and are smaller than the pores of the membranes in the oral cavity or the GI tract. It is therefore believed that the extremely small size of mixed micelles helps encapsulated molecules penetrate efficiently through the mucosal membranes of the oral cavity. The absorption of proteins and peptides is believed to be enhanced by the diffusion of large molecules entrapped in the mixed micellar form through the aqueous pores and the cell structure perturbation of the tight paracellular junctions.
- the amount of physiologically peptide or protein in the compositions of this invention is typically a quantity that provides an effective amount of the drug to produce the physiological activity (therapeutic plasma level) for which peptide or protein is being administered.
- the bioavailability of any active substance can never be 100%, that is to say the administered dose of the active drug is not completely absorbed, it is preferable to incorporate slightly larger amount than the desired dosage.
- the dosage form is a spray (aerosol) or the like which is repeatedly dispensed from the same container, it is recommendably so arranged that the unit dose will be slightly greater than the desired dose. It should be understood that dosage should vary with species of warm blood animals such as man, domestic animals, and their body weights.
- composition of this invention is prepared as the microfine droplets (1 to 10 nm or less) by the virtue of its preparation methods used and suitable combinations of enhancer compound characteristics.
- atomizer or aerosol spray devices may be useful to further a sufficient reduction of particle size for effective inhalation from the nasal or oral cavity so the drug may successfully absorbed or reach to the specific site.
- the therapeutic composition of the present invention can be stored at room temperature or at cold temperature. Storage of proteinic drugs is preferable at the cold temperature to prevent the degradation of the drugs and to extend their shelf life. While the mixed micellar therapeutic composition of the invention is applied to the mucosal membranes, the sites of administration may the same as those used for the usual mucosal therapeutic preparation. Generally, oral, transdermal and nasal are the favourite sites of the administration but the composition can be applied to the rectal and vaginal mucosa. According to the physiologically active peptide or protein used, the dosage form and the site of administration, a specific administration method can be selected.
- edetate is used herein to refer to pharmaceutically acceptable salts of ethylenediaminetetraacetic acid. It has also been found that improvements in penetration and absorption of mixed micellar formulations can be achieved by mixing the mixed micellar formulation with propellants such as tetrafluoroethane, heptafluoroethane, dimethylfluoropropane, tetrafluoropropane, butane, isobutane, dimethyl ether and other non-CFC and CFC propellants. Preferably they are delivered through metered dose spray devices. Metered dose inhalers are known and are a popular pulmonary drug delivery form for some drugs.
- the present formulation including the propellant is intended to improve the quality of absorption, stability and performance of many formulations.
- the compositions have been selected to give enhancement in the penetration through pores, and facilitate absorption of the drugs to reach therapeutic levels in the plasma.
- the present formulation may be absorbed buccally, by ensuring that the person does not inhale the formulation as it is sprayed.
- One of the other benefits of using an atomizer or inhaler is that the potential for contamination is minimized because the devices are self contained.
- the present invention provides a mixed micellar pharmaceutical formulation
- a mixed micellar pharmaceutical formulation comprising a proteinic pharmaceutical agent in micellar form, water, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt./wt.% of the total formulation, a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the total formulation, at least one alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the total formulation, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, gly
- the alkali metal lauryl sulphate, the edetate and the alkali metal salicylate are each in a concentration of from 2 to 5 wt./wt.% of the total formulation.
- the edetate is an alkali metal edetate.
- the alkali metal edetate is be selected from the group consisting of disodium edetate, dipotassium edetate, and combinations thereof.
- the alkali metal lauryl sulphate is sodium lauryl sulphate.
- the alkali metal salicylate is sodium salicylate.
- the lecithin is selected from the group consisting of saturated phospholipid, e.g. Phospholipon-H (trade mark) saturated phospholipid, unsaturated phospholipid, e.g. Phospholipon-G (trade mark) unsaturated phospholipid, phosphatidylcholine, phosphatidyl serine, sphingomyelin, phosphatidylethanolamine, cephalin, and lysolecithin.
- saturated phospholipid e.g. Phospholipon-H (trade mark) saturated phospholipid
- unsaturated phospholipid e.g. Phospholipon-G (trade mark) unsaturated phospholipid
- phosphatidylcholine phosphatidyl serine
- sphingomyelin phosphatidylethanolamine
- cephalin cephalin
- lysolecithin lysolecithin
- one of the absorption enhancing compounds is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid and mixtures thereof, the concentration such micelle forming compound being from about 1 to about 5 wt./wt.%.
- suitable for delivery through nasal passages mixed micellar pharmaceutical formulation is suitably diluted to avoid irritation of the nasal passages.
- Another aspect of the present invention provides a mixed micellar pharmaceutical formulation, comprising a pharmaceutical agent in micellar form, water, an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 10 wt./wt.% of the total formulation, a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the total formulation, at least one alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the total formulation, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, menthol, trihydroxy oxo cholanylglycine and pharmaceutically
- the mixed micellar aerosol pharmaceutical formulation additionally comprises i) a phenol selected from the group consisting of phenol and methyl phenol in a concentration of from 1 to 10 wt./wt.% of the total formulation, and i) a propellant selected from the group consisting of C1-C2 dialkyl ether, butanes, fluorocarbon propellant, hydrogen-containing fluorocarbon propellant, chlorofluorocarbon propellant, hydrogen-containing chlorofluorocarbon propellant, and mixtures thereof.
- the alkali metal C8 to C22 alkyl sulphate is in a concentration of from 2 to 5 wt./wt.% of the total formulation.
- the alkali metal C8 to C22 alkyl sulphate is sodium lauryl sulphate.
- the lecithin is saturated or unsaturated, preferably selected from the group consisting of phosphatidylcholine, phosphatidyl serine, sphingomyelin, phosphatidylethanolamine, cephalin, and lysolecithin.
- one of the micelle forming compounds is selected from the group consisting of hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, polidocanol alkyl ethers, trihydroxy oxo cholanyl glycine, polyoxyethylene ethers and mixtures thereof, the concentration such absorption enhancing compound being from about 1 to about 5 wt./wt.%.
- the ratio of pharmaceutical agent, e.g. insulin, to propellant is from 5:95 to 25:75.
- the propellant is selected from the group consisting of tetrafluoroethane, tetrafluoropropane, dimethylfluoropropane, heptafluoropropane, dimethyl ether, n-butane and isobutane.
- the mixed micellar pharmaceutical formulation is contained in an aerosol dispenser.
- the composition may also contains at least one inorganic salt which opens channels in the gastrointestinal tract and may provide additional stimulation to release insulin.
- inorganic salts are sodium, potassium, calcium and zinc salts, especially sodium chloride, potassium chloride, calcium chloride, zinc chloride and sodium bicarbonate.
- flavouring agents are menthol and sorbitol.
- the antioxidant is selected from the group consisting of tocopherol, deteroxime mesylate, methyl paraben, ethyl paraben and ascorbic acid and mixtures thereof.
- a preferred antioxidant is tocopherol.
- At least one protease inhibitor is added to the formulation to inhibit degradation of the pharmaceutical agent by the action of proteolytic enzymes.
- protease inhibitors most are effective at concentrations of from 1 to 3 wt./wt.% of the formulation.
- Non-limiting examples of effective protease inhibitors are bacitracin, soyabean trypsin, aprotinin and bacitracin derivatives, e.g. bacitracin methylene disalicylate.
- Bacitracin is the most effective of those named when used in concentrations of from 1.5 to 2 wt./wt.%. Soyabean trypsin and aprotinin two may be used in concentrations of about 1 to 2 wt./wt.% of the formulation.
- the formulation suitable for delivery through oral mucosal membranes may be in chewable form, in which case it will be necessary to add ingredients suitable for such form. Such ingredients include guar gum, powdered acacia, carrageenin, beeswax and xanthan gum.
- the pharmaceutical agent may be selected from a wide variety of macromolecular agents, depending on the disorder being treated, generally with molecular weights greater than about 1000 and especially between about 1000 and 2 000 000.
- Preferred pharmaceutical agents are selected from the group consisting of insulin, heparin, low molecular weight heparin, hirulog, hirugen, huridine, interferons, interleukins, cytokins, mono and polyclonal antibodies, immunoglobins, chemotherapeutic agents, vaccines, glycoproteins, bacterial toxoids, hormones, calcitonins, insulin like growth factors (IGF), glucagon like peptides (GLP-1), large molecule antibiotics, protein based thrombolytic compounds, platelet inhibitors, DNA, RNA, gene therapeutics and antisense oligonucleotides, and small molecule drugs, e.g. opioids, narcotics, analgesics, NSAIDS, steroids, hypnotics, pain killers, morph
- the present invention also provides a process for making a pharmaceutical composition suitable for delivery through transdermal membranes comprising: a) preparing a proteinic pharmaceutical agent composition in micellar form in an aqueous medium which has an alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition and a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition; b) slowly adding the micellar proteinic pharmaceutical agent composition to at least one of the absorption enhancing compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic
- the process provides an additional step of adding, while continuing vigorous mixing, at least one absorption enhancing compound different from that added in step b), selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein, chenodeoxycholate, deoxycholate and mixtures thereof.
- at least one absorption enhancing compound different from that added in step b) selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid,
- alkali metal lauryl sulphate is sodium lauryl sulphate.
- alkali metal salicylate is sodium salicylate.
- the alkali metal edetate may be selected from the group consisting of disodium edetate and dipotassium edetate.
- the formulation has a combinations selected from the group consisting of sodium hyaluronate and unsaturated phospholipid, ii) Phospholipon-H and glycolic acid, and iii) sodium hyaluronate and lecithin.
- the present invention also provides a process for making a pharmaceutical composition suitable for delivery by means of an aerosol comprising: a) preparing a pharmaceutical agent composition in micellar form in an aqueous medium which has an alkali metal C8 to C22 alkyl sulphate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition, a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition, at least one alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the aqueous micellar pharmaceutical agent composition; b) slowly adding the micellar proteinic pharmaceutical agent composition to at least one of the absorption enhancing compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glyco
- the vigorous mixing may be accomplished using high speed stirrers,
- the vigorous mixing may be accomplished by using high speed stirrers, e.g. magnetic stirrers or propellor stirrers, or by sonication.
- the mixed micellar formulation is formed by sonication of the aqueous micellar pharmaceutical agent composition in the presence of lecithin.
- the present invention also provides a metered dose aerosol dispenser with the composition of the present invention therein.
- the present invention also provides a method for administering mixed micellar pharmaceutical formulations of the present invention, by spraying the intermixed composition into the mouth with a metered dose spray device.
- the present invention also provides a method for administration of a proteinic pharmaceutical agent in a buccal cavity of a human being by spraying into the cavity, without inhalation, from a metered dose spray dispenser, a mixed micellar pharmaceutical formulation and a propellant comprising: i) a proteinic pharmaceutical agent in micellar form, water, an alkali metal lauryl sulphate in a concentration of from 1 to 10 wt./wt.% of the total formulation, a pharmaceutically acceptable edetate in a concentration of from 1 to 10 wt./wt.% of the total formulation, at least one alkali metal salicylate in a concentration of from 1 to 10 wt./wt.% of the total formulation, and at least one micelle forming compound selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract,
- the present invention provides an improved method for delivery of macromolecular (high molecular weight) pharmaceutical agents, particularly through the membranes in the nose, mouth, vagina or rectum.
- the preferred delivery is through oral and nasal cavities.
- the pharmaceutical agents cover a wide spectrum of agents, including proteins, peptides, hormones, vaccines and drugs.
- the molecular weights of the macromolecular pharmaceutical agents are preferably above 1000, especially between 1000 and 2 000 000.
- hormones which may be administered with the present invention include thyroids, androgens, estrogens, prostaglandins, somatotropins, gonadotropins, erythropoetin, interferons, interleukins, steroids and cytokins.
- Vaccines which may be administered with the present invention include bacterial and viral vaccines such as vaccines for hepatitis, influenza, tuberculosis, canary pox, chicken pox, measles, mumps, rubella, pneumonia, BCG, HIV and AIDS.
- Bacterial toxoids which may be administered using the present invention include diphtheria, tetanus, pseudonomas and mycobactrium tuberculosis.
- the concentration of the pharmaceutical agent is an amount sufficient to be effective in treating or preventing a disorder or to regulate a physiological condition in an animal or human.
- the concentration or amount of pharmaceutical agent administered will depend on the parameters determined for the agent and the method of administration, e.g. oral, nasal.
- nasal formulations tend to require much lower concentrations of some ingredients in order to avoid irritation or burning of the nasal passages. It is sometimes desirable to dilute an oral formulation up to 10-100 times in order to provide a suitable nasal formulation.
- the mixed micellar formulation is prepared by first preparing a first micellar composition which contains the pharmaceutically active agents, alkali metal C8 to C22 alkyl sulphate, edetate and alkali metal salicylate.
- the first micellar composition is then added to at least one of the absorption enhancing compounds to form a mixed micellar composition.
- At least one other abso ⁇ tion enhancing compound may also be added subsequently.
- the first abso ⁇ tion enhancing compound is lecithin.
- the phenol and/or m-cresol and/or isotonic agent, e.g. glycerin are then added.
- the formulation is then put into an aerosol dispenser and the dispenser charged with the propellant.
- the propellant which is under pressure, is in liquid form in the dispenser.
- the aqueous phase may be separated from the propellant phase.
- the ratios of the ingredients are adjusted by simple experimentation so that the aqueous and propellant phases become one, i.e. there is one phase. If there are two phases, it is necessary to shake the dispenser prior to dispensing a portion of the contents, e.g. through a metered valve. The dispensed dose of pharmaceutical agent is propelled from the metered valve in a fine spray.
- the preferred propellants are hydrogen-containing chlorofluorocarbons, hydrogen-containing fluorocarbons, dimethyl ether and diethyl ether. Even more preferred is hydrofluoroalkane (HFA) 134a (1,1,1,2 tetrafluoroethane).
- HFA hydrofluoroalkane
- compositions of the present invention require that the pharmaceutical formulation be in mixed micellar form.
- the first micellar solution may be made by adding a buffer solution to powdered insulin, and then stirring until the powder is dissolved and a clear solution is obtained.
- a typical buffer solution is an aqueous solution of sodium salicylate and sodium lauryl sulphate and disodium edetate. Typical concentration of sodium salicylate and sodium lauryl sulphate in the aqueous solution are about 3 to 20 wt./wt.% of each compound in the solution.
- insulin is present in the micellar solution in an amount which will give a concentration of about 2 to 4 wt./wt.% of the final formulation. Typically the concentration may be about 10 wt./wt.% of the first micellar composition.
- micellar solution is then added slowly to the first abso ⁇ tion enhancing compound, e.g. lecithin while mixing vigorously, e.g. sonicating, to form a mixed micelle liposomal solution.
- At least one other abso ⁇ tion enhancing compounds selected from the group consisting of lecithin, hyaluronic acid, pharmaceutically acceptable salts of hyaluronic acid, octylphenoxypolyethoxyethanol, glycolic acid, lactic acid, chamomile extract, cucumber extract, oleic acid, linolenic acid, borage oil, evening of primrose oil, trihydroxy oxo cholanylglycine, glycerin, polyglycerin, lysine, polylysine, triolein, chenodeoxycholate, deoxycholate is then added.
- the mixing may be done with a high speed mixer or sonicator to ensure uniform micelle particle size distribution within the formulation.
- Each of the abso ⁇ tion enhancing compounds when present, is in a concentration of from 1 to 10 wt./wt.% of the total formulation.
- Preferred salts of hyaluronic acid are alkali metal hyaluronates, alkaline earth hyaluronates and aluminium hyaluronate.
- the preferred salt is sodium hyaluronate.
- the preferred concentration of hyaluronic acid or pharmaceutically acceptable salts of hyaluronic acid is from 1 to 5 wt./wt.% of the total formulation. An even more preferred range is from 1.5 to 3.5 wt./wt.% of the total formulation.
- Other ingredients may be added to the mixed micellar solution. For example, flavouring agents, antioxidants, salts, protease inhibitors or other pharmaceutically acceptable compound may be added.
- the size of the micelle particles in the solution is about 1 to 10 nm, and preferably from 1 to 5 nm. Such a size distribution ensures effective abso ⁇ tion of the formulation, and therefore the pharmaceutical agent, through the membranes, for example the membranes in the oral and nasal cavities.
- the specific concentrations of the essential ingredients can be determined by relatively straightforward experimentation. For abso ⁇ tion through the nasal and oral cavities, it is often desirable to increase, e.g. double or triple, the dosage which is normally required through injection of administration through the gastrointestinal tract.
- the amount of each component of the formulation will vary depending on the pharmaceutical agent and the site of application.
- Preferred formulations oral or nasal application have the following combinations: i) sodium lauryl sulphate, sodium salicylate, disodium edetate, Phospholipon-H and sodium hyaluronate; ii) sodium lauryl sulphate, sodium salicylate, disodium edetate, lecithin and sodium hyaluronate; iii) sodium lauryl sulphate, sodium salicylate, disodium edetate, sodium hyaluronate and evening of primrose oil; iv) sodium lauryl sulphate, sodium salicylate, disodium edetate, Phospholipon-H and bacitracin; v) sodium lauryl sulphate, sodium salicylate, disodium edetate, Phospholipon-H, sodium hyaluronate and bacitracin; vi) sodium lauryl sulphate, sodium salicylate, disodium edetate, sodium hyal
- aerosol formulations For aerosol formulations, the addition of a mixture of phenol and m-cresol is preferred. Such an aerosol formulation may then be charged to an aerosol dispenser and then charged with a propellant, preferably a non-CFC propellant.
- a propellant preferably a non-CFC propellant.
- the therapeutic compositions of the present invention may be stored at room temperature or at cold temperature. Storage of proteinic drugs is preferable at a cold temperature to prevent degradation of the drugs and to extend their shelf life.
- oral and nasal are the favourite sites of the administration but the composition can be applied to the rectal and vaginal mucosa.
- the dosage form and the site of administration a specific administration method can be selected.
- the composition of this invention is generally prepared as microfine mixed micellar particles (1 to 10 nm or less) by the virtue of its preparation methods used and suitable combinations of abso ⁇ tion enhancer characteristics.
- size of the micelle particles in the mixed micellar composition is about 1 to 5 nm.
- Such mixed micelles tend to be smaller than the pores of the membranes in the oral cavity or the GI tract. It is therefore believed that the extremely small size of mixed micelles helps the encapsulated molecules penetrate efficiently through the mucosal membranes of the oral cavity.
- the desired size of aerosol droplets which are sprayed from the aerosol dispenser will depend, in part, on where the pharmaceutical is to be deposited. For example, for deposition in the lungs, particle sizes of less than about 5 ⁇ m are preferred whereas for abso ⁇ tion in the buccal cavity of the mouth, particle sizes of about 6- 10 ⁇ m are preferred.
- sprays are preferable, but also drops, chewable tablets, chewable gum and other suitable forms may be used.
- Utilization of atomizer or aerosol spray devices can be used to further reduce the particle size for effective inhalation from the nasal or oral cavity so the drug may successfully reach to the specific site and be absorbed. It is also possible to utilize a drug delivery system such that an enteric coating is applied to the gelatin capsule to cause the micelles to be released only in the duodenum or in the proximity of the large intestine and not in the stomach.
- the present formulation including the propellant, is intended to improve the quality of abso ⁇ tion, stability and performance of many formulations.
- the compositions have been selected to give enhancement in the penetration through pores, and facilitate abso ⁇ tion of the drugs to reach therapeutic levels in the plasma.
- Administration of the formulation into the buccal cavity is by spraying the formulation into the mouth, without inhalation, so that the droplets stay in the mouth rather than be drawn into the lungs.
- a solution was prepared using 0.5 g sodium lauryl sulphate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. To this solution 40 mg (1000 units) of insulin was added and dissolved completely while stirring, to give about 100 units/mL insulin solution.
- Time* 0 15 30 60 75 90 120 150 180
- Oral insulin (100 units) was formulated in (Phospholipon-H, 10 mg) without any sodium lauryl sulphate, sodium salicylate, edetate or abso ⁇ tion enhancers, to evaluate its efficacy of blood glucose lowering in a fasted state, for healthy volunteers.
- Example 3 A further experiment, not within the scope of the present invention, was performed for comparative pu ⁇ oses.
- Oral insulin (100 units) was formulated with sodium salicylate and alkali metal edetate (both 5% by wt.) to evaluate its efficacy of blood glucose lowering in fasted state in healthy volunteers. Volunteers were asked to fast overnight and not have any breakfast prior to dosing. Volunteers were asked to take this oral insulin formulation in their mouth and swallow it. Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the average results for 5 volunteers are shown in Table
- Oral insulin (100 units) was formulated using sodium salicylate and alkali metal edetate (both 5% by wt.) with Phospholipon-H (10 mg) and tested on healthy subjects. Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the results are shown in Table V. T TJable V Time*: 0 15 30 45 60 90 120 180
- Oral insulin (50 units) was formulated using only alkali metal lauryl sulphate (5% by wt). Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the average results for four volunteers are shown in Table VI. Table VI
- Time* 0 15 30 60 90 120 180
- Example 6 Yet another experiment, within the scope of the present invention, was performed.
- micellar oral insulin 50 units was formulated using alkali metal lauryl sulphate and sodium salicylate (both 4.4% by wt.) and alkali metal edetate (2.2% by wt) with Phospholipon-H (10 mg) and tested on healthy volunteers.
- the method involved mixing the sodium lauryl sulphate, sodium salicylate and alkali metal edetate with water in a beaker with a magnetic stirrer at medium speed until the ingredients were dissolved, to form buffer solution. Insulin powder was placed in a beaker and to this powder was added the buffer solution. The solution was continuously stirred using a magnetic stir bar until all of the insulin powder was dissolved and a clear solution obtained.
- the micellar solution so formed was stored in clean glass bottles and refrigerated.
- micellar liposomal insulin was then prepared in a glass beaker, in which was placed the Phospholipon-H and a small amount of isopropyl alcohol. The mixture was stirred at a high speed (1000 rpm) for about 10 minutes to ensure complete dissolution of the Phospholipon-H. To this solution was added the micellar insulin solution very slowly, drop wise, using glass dropper, with continuous stirring at a high speed. The solution was stirred continuously for another 30 minutes at a high speed to ensure uniform micellar particle size distribution.
- micellar solution samples were taken orally by the volunteers. Blood glucose levels were monitored every 15 minutes using Bayer's glucometer Elite for 3 hours and the average results for 5 volunteers are shown in Table VII.
- the formulation was for oral administration.
- Oral insulin (50 units) was formulated using alkali metal lauryl sulphate and sodium salicylate (both 4.4% by wt.) and alkali metal edetate (2.2% by wt.) with Phospholipon-H ( 10 mg) and sodium hyaluronate ( 1.1 % by wt).
- This formulation was tested on healthy subjects under fasting condition.
- the method involved mixing the sodium lauryl sulphate, sodium salicylate and alkali metal edetate with water in a beaker with a magnetic stirrer at medium speed until the ingredients were dissolved, to form buffer solution. Insulin powder was placed in a beaker and to this powder was added the buffer solution. The solution was continuously stirred using a magnetic stir bar until all of the insulin powder was dissolved and a clear solution obtained.
- the micellar solution so formed was stored in clean glass bottles and refrigerated.
- micellar liposomal insulin was then prepared in a glass beaker, in which was placed the Phospholipon-H and a small amount of isopropyl alcohol. The mixture was stirred at a high speed (1000 rpm) for about 10 minutes to ensure complete dissolution of the Phospholipon-H. To this solution was added the micellar insulin solution very slowly, drop wise, using glass dropper, with continuous stirring at a high speed. The solution was stirred continuously for another 30 minutes at a high speed to ensure uniform micellar particle size distribution. The hyaluronate and small amounts of menthol and sorbitol were then added, with continuous stirring.
- Time* 0 15 30 45 60 90 120 150 180
- Example 8 A further experiment, within the scope of the present invention, was performed.
- the formulation was for oral administration.
- a buffer solution was prepared using 0.5 g sodium lauryl sulphate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. The solution was added to insulin and mixed, to form micellar insulin.
- micellar insulin solution dissolved in 3 mL of the buffer solution to (give 30 units/mL insulin solution) was added slowly with vigorous mixing, to form a mixed micellar solution.
- 0.6 mL of sodium hyaluronate and 0.2 ml of 2% menthol solution containing 3% sorbitol were studied.
- the volunteers were tested with insulin, taken orally. The volunteers fasted from midnight prior to the test, with no food being taken during the 4 hour study.
- the volunteers received 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly).
- the volunteers received 30 units (1 mL volume per drop, approximately 20 drops) of the above- prepared oral insulin (3 times the injection dose).
- blood glucose levels were monitored every 15 minutes by Bayer's Glucometer Elite.
- Example 9 This example illustrates a method for making a mixed micellar formulation according to the present invention.
- micellar insulin solution was then prepared in a 50 mL capacity glass beaker, into which was placed 11.54 mg insulin powder. To this powder was added 10 mL of the buffer solution. The solution was continuously stirred using a magnetic stir bar until all of the insulin powder was dissolved and a clear solution obtained. The micellar solution so formed was stored in clean glass bottles and refrigerated.
- a 2% menthol solution was then prepared from 100 mg menthol crystals, dissolved in 5 mL ethanol. To this solution was added 5 mg FD & C blue dye. The solution was stirred for 10 minutes and stored in a glass bottle at room temperature.
- phosphatidylcholine Sigma
- phosphatidylcholine powder does not dissolve completely, then heating up to about 45 °C may be required, e.g. using a water bath.
- micellar insulin composition is not added slowly, then the mixed micellar formulation will not be formed and the formulation will be gelatinous and sticky.
- Example 9 The formulation of Example 9 was tested in a manner similar to that indicated in Example 8 except that the formulation of the present invention was administered nasally.
- the ten volunteers each received 10 units insulin injection (regular fast acting, Eli Lilly).
- the volunteers received 20 units of the "oral" insulin of Example 9 (2 times the injection dose).
- the "oral” insulin was administered as drops (0.4 mL volume per drop, approximately 4 large drops in total, i.e. two drops in each nostril).
- results show that the nasal insulin formulation of the present invention, at a dosage of twice the injected level, is comparable to the injected insulin.
- Example 9 The formula of Example 9 was taken and tests performed to determine the insulin action on meal glucose on healthy volunteers.
- Example 9 The mixed micellar formulation of Example 9 was tested in healthy volunteers under controlled conditions to determine the oral insulin effect on meal glucose when compared to injected insulin. In one set of tests, ten healthy non-diabetic human volunteers were tested with insulin, by injection. In another set of tests the volunteers were tested with insulin, taken orally. The volunteers fasted from midnight prior to the tests, with food being taken 30 minutes after dosing. The meals were standard Sastacal 240 mL liquid diet approved by the Diabetic Society, containing 400 calories.
- Example 12 The mixed micellar formulation of Example 9 was tested in diabetic volunteers under controlled conditions to determine the oral insulin effect on meal glucose when compared to injected insulin.
- the volunteers received 10 units insulin by injection (regular fast acting insulin, available from Eli Lilly).
- the volunteers received 30 units of the above-prepared oral insulin (3 times the injection dose).
- blood glucose levels were monitored every 15 minutes by Bayer's Glucometer Elite.
- a chewable gum insulin formulation was prepared by vigorously stirring the liposomal insulin mixed micellar solution of Example 9 while adding guar gum, beeswax, powdered acacia, oleic acid, gamma-linoleic acid and sorbitol.
- the mixture contained 100 mg guar gum, 50 mg beeswax, 50 mg powdered acacia, 100 mg oleic acid, 100 mg gamma-linoleic acid and 1 mL 3% sorbitol in ethanol solution.
- the mixture was then poured into a flat tray coated with polytetrafluoroethylene until the mixture was about 10 mm deep.
- the mixture then solidified and after solidification was cut into sticks about 1 cm by 3 cm. Each stick contained about 30 units insulin.
- the mixed micellar formulation in chewable stick form was tested in diabetic volunteers under controlled conditions to determine the oral insulin effect on meal glucose when compared to injected insulin.
- the formulation was for oral administration.
- a buffer solution was prepared using 0.5 g sodium lauryl sulphate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. The solution was added to 8 mg (200 units) insulin and mixed, to form micellar insulin.
- micellar solution were added 0.2 g bacitracin and 0.5 g evening of primrose oil and the solution was mixed vigorously to form a mixed micellar insulin solution (about 20 units/mL).
- micellar insulin solution which had been prepared from an aqueous solution of insulin, sodium lauryl sulphate, sodium salicylate and disodium edetate.
- the flask was shaken with the help of shaker plate. Shaking was continued for at least 30 minutes and then the solution was sonicated with a high frequency sonicating probe for another 60 minutes in order to form small uniform mixed micelles.
- the mixed micelles so obtained were analyzed by Malvern Zeta (trade mark) particle size distribution measurement equipment equipped with the laser light scattering device.
- the mixed micelles particle size distribution obtained by this method was between 2 and 9nm.
- To this solution was added 1 mL of 2% menthol solution and 50 mg sodium hyaluronate.
- the semi-clear, translucent, light blue colour solution (final volume 10 mL) was stored in a clean glass bottle and refrigerated.
- the solution had a pH of 6.5.
- a buffer solution was prepared using 0.5 g sodium lauryl sulphate, 0.5 g sodium salicylate and 0.25 g disodium edetate dissolved in 10 mL of water. The solution was added to 8 mg (200 units) insulin and mixed, to form micellar insulin.
- micellar solution were added 0.5 g borage oil and the solution was mixed vigorously to form a mixed micellar insulin solution (about 20 units/mL).
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ517313A NZ517313A (en) | 1999-08-31 | 2000-08-25 | Mixed micellar pharmaceutical delivery system and method of preparation |
CA002382535A CA2382535C (en) | 1999-08-31 | 2000-08-25 | Mixed micellar pharmaceutical delivery system and method of preparation |
JP2001519880A JP2003508421A (en) | 1999-08-31 | 2000-08-25 | Mixed micelle drug delivery system and preparation method |
MXPA02002267A MXPA02002267A (en) | 1999-08-31 | 2000-08-25 | Mixed micellar pharmaceutical delivery system and method of preparation. |
AU68143/00A AU763251B2 (en) | 1998-02-10 | 2000-08-25 | Mixed micellar pharmaceutical delivery system and method for preparation |
EP00956008A EP1207853A1 (en) | 1999-08-31 | 2000-08-25 | Mixed micellar pharmaceutical delivery system and method of preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/386,285 US6221378B1 (en) | 1998-02-10 | 1999-08-31 | Mixed micellar delivery system and method of preparation |
US09/386,285 | 1999-08-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001015666A1 true WO2001015666A1 (en) | 2001-03-08 |
Family
ID=23524958
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CA2000/001019 WO2001015666A1 (en) | 1998-02-10 | 2000-08-25 | Mixed micellar pharmaceutical delivery system and method of preparation |
Country Status (7)
Country | Link |
---|---|
US (1) | US6221378B1 (en) |
EP (1) | EP1207853A1 (en) |
JP (1) | JP2003508421A (en) |
CA (1) | CA2382535C (en) |
MX (1) | MXPA02002267A (en) |
NZ (1) | NZ517313A (en) |
WO (1) | WO2001015666A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001072278A2 (en) * | 2000-03-30 | 2001-10-04 | Generex Pharmaceuticals Inc. | Method for administering insulin to the buccal region |
WO2004016244A2 (en) | 2002-08-16 | 2004-02-26 | Generex Pharmaceuticals Inc. | Pharmaceutical compositions for buccal delivery of pain relief medications |
EP1452162A1 (en) * | 2001-11-09 | 2004-09-01 | The Nisshin Oil Mills, Ltd. | Gel-form composition |
WO2005065714A1 (en) * | 2003-12-26 | 2005-07-21 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
JPWO2004037859A1 (en) * | 2002-10-11 | 2006-02-23 | 株式会社三和化学研究所 | GLP-1 derivative and transmucosal absorption preparation thereof |
EP1661556A1 (en) * | 2003-08-20 | 2006-05-31 | Ajinomoto Co., Inc. | Medicinal preparation having improved dissolution properties |
AU2003263416B2 (en) * | 1998-12-21 | 2008-03-06 | Generex Pharmaceuticals Inc. | Pharmaceutical compositions for buccal delivery of pain relief medications |
FR2906140A1 (en) * | 2006-09-22 | 2008-03-28 | Philippe Perovitch | GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2686899B1 (en) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
US7070799B1 (en) * | 1998-02-10 | 2006-07-04 | Generex Pharmaceuticals, Inc. | Method for administering insulin to the buccal region |
US7087215B2 (en) * | 1998-12-21 | 2006-08-08 | Generex Pharmaceuticals Incorporated | Methods of administering and enhancing absorption of pharmaceutical agents |
US6451286B1 (en) * | 1998-12-21 | 2002-09-17 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary administration comprising an alkali metal alkyl sulfate and at least three micelle-forming compounds |
US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
US6350432B1 (en) * | 1999-03-19 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Pressurized container having an aerosolized pharmaceutical composition |
DE10007771A1 (en) * | 2000-02-14 | 2001-08-23 | Kleine & Steube Entoxin Gmbh | Immunomodulatory compositions, processes for their preparation and their use |
US6432383B1 (en) * | 2000-03-30 | 2002-08-13 | Generex Pharmaceuticals Incorporated | Method for administering insulin |
EP1274720A4 (en) * | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | Albumin fusion proteins |
US20020141970A1 (en) * | 2001-03-05 | 2002-10-03 | Pettit Dean K. | Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
CA2446739A1 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
CN1335182A (en) * | 2001-08-08 | 2002-02-13 | 华中科技大学 | Insulin spray for oral cavity and its prepn process |
CA2841097A1 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
CA2484556A1 (en) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2003209750A1 (en) * | 2002-03-30 | 2003-10-13 | Gunther Beisel | Preparation containing fatty acid, used for reducing appetite, satiating, and/or reducing weight |
EP1369113B1 (en) * | 2002-06-06 | 2006-11-22 | CHIESI FARMACEUTICI S.p.A. | Solubilisation of drugs in HFA propellant by means of emulsions |
GB2399752A (en) * | 2003-03-26 | 2004-09-29 | Micap Plc | Pharmaceutical composition comprising a fungal cell or cell fragment as adjuvant |
FR2854072B1 (en) * | 2003-04-23 | 2006-08-04 | Centre Nat Rech Scient | VECTOR FOR ORAL ADMINISTRATION |
US20050238632A1 (en) * | 2004-04-23 | 2005-10-27 | Alburty David S | Propellant formulations |
MXPA06012489A (en) * | 2004-04-28 | 2007-02-08 | Procarrier Inc | Oral formulation for delivery of poorly absorbed drugs. |
US7754230B2 (en) * | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
TR201802446T4 (en) * | 2004-05-19 | 2018-03-21 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Injectable composition containing sodium deoxycholate. |
US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
ES2355642T3 (en) * | 2004-07-16 | 2011-03-29 | Nektar Therapeutics | CONJUGATES UNDERSTANDING A PORTION OF GM-CSF AND A POLYMER. |
PL1933809T3 (en) * | 2005-10-11 | 2012-09-28 | Yissum Research Development Company Of The Hebrew Univ Of Jerusalem | Compositions for nasal delivery |
EA015399B1 (en) * | 2007-11-15 | 2011-08-30 | Ргкп Научно-Исследовательский Институт Кардиологии И Внутренних Болезней Министерства Здравоохранения Республики Казахстан | Method for the treatment of viral myocarditis |
US8986253B2 (en) | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
AU2009293019A1 (en) | 2008-09-19 | 2010-03-25 | Tandem Diabetes Care Inc. | Solute concentration measurement device and related methods |
EP2401587A2 (en) | 2009-02-27 | 2012-01-04 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
US9250106B2 (en) | 2009-02-27 | 2016-02-02 | Tandem Diabetes Care, Inc. | Methods and devices for determination of flow reservoir volume |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
EP2429503A1 (en) * | 2009-05-13 | 2012-03-21 | Protein Delivery Solutions, LLC | Pharmaceutical system for trans-membrane delivery |
CA2769030C (en) | 2009-07-30 | 2016-05-10 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
WO2011064316A2 (en) | 2009-11-25 | 2011-06-03 | Paolo Botti | Mucosal delivery of peptides |
US20120201857A1 (en) * | 2010-03-17 | 2012-08-09 | Pankaj Modi | Transdermal delivery system for therapeutics |
EP2675460A4 (en) | 2011-02-18 | 2014-07-09 | Kythera Biopharmaceuticals Inc | Treatment of submental fat |
US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
US11166912B2 (en) * | 2016-03-03 | 2021-11-09 | Ctt Pharma Inc. | Orally administrable composition |
AU2019396217A1 (en) * | 2018-12-10 | 2021-07-08 | Halo Science LLC | Stable formulations of anesthetics and associated dosage forms |
US11298336B2 (en) | 2019-05-30 | 2022-04-12 | Soluble Technologies, Inc. | Water soluble formulation |
US11786475B2 (en) | 2020-07-22 | 2023-10-17 | Soluble Technologies Inc. | Film-based dosage form |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026302A1 (en) * | 1993-05-12 | 1994-11-24 | Genentech, Inc. | Stable liquid compositions of gamma interferon |
WO1996019197A1 (en) * | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol formulations of peptides and proteins |
WO1996036352A1 (en) * | 1995-05-16 | 1996-11-21 | Pankaj Modi | Liquid formulations for proteinic pharmaceuticals comprising at least 2 absorption enhancers |
WO1999040932A1 (en) * | 1998-02-10 | 1999-08-19 | Generex Pharmaceuticals, Inc. | Mixed micellar pharmaceutical delivery system and method of preparation |
WO2000037051A1 (en) * | 1998-12-21 | 2000-06-29 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2055083A (en) | 1932-07-13 | 1936-09-22 | Winthrop Chem Co Inc | Pharmaceutical preparation |
DE1792410B2 (en) | 1967-09-01 | 1980-03-13 | Apoteksvarucentralen Vitrum Apotekareaktiebolaget, Stockholm | Medicinal preparation for intravenous injection |
US4464363A (en) | 1979-12-20 | 1984-08-07 | Merck & Co., Inc. | Ajuvants for rectal delivery of drug substances |
EP0037943B1 (en) | 1980-03-31 | 1985-08-14 | Teijin Limited | Pharmaceutical composition for intrarectal administration, and suppository prepared therefrom |
US4900730A (en) | 1981-01-14 | 1990-02-13 | Toyo Jozo Co., Ltd. | Preparation which promotes the absorption of peptides |
NL193099C (en) | 1981-10-30 | 1998-11-03 | Novo Industri As | Stabilized insulin solution. |
US4582820A (en) | 1982-12-23 | 1986-04-15 | Research Corporation | Orally administered biologically active peptides and proteins |
IL68769A (en) | 1983-05-23 | 1986-02-28 | Hadassah Med Org | Pharmaceutical compositions containing insulin for oral administration |
US4849405A (en) | 1984-05-09 | 1989-07-18 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
US4963367A (en) | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US4963526A (en) | 1984-05-09 | 1990-10-16 | Synthetic Blood Corporation | Oral insulin and a method of making the same |
JPS61267528A (en) | 1984-11-26 | 1986-11-27 | Yamanouchi Pharmaceut Co Ltd | Transnasal calcitonin agent containing absorbefacient |
US5288497A (en) | 1985-05-01 | 1994-02-22 | The University Of Utah | Compositions of oral dissolvable medicaments |
US4729989A (en) | 1985-06-28 | 1988-03-08 | Merck & Co., Inc. | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts |
US4822773A (en) | 1985-06-28 | 1989-04-18 | Merck & Co., Inc. | Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts |
US4973579A (en) | 1985-06-28 | 1990-11-27 | Merck & Co., Inc. | Enhancment of absorption of drugs from gastrointestinal tract using choline ester salts |
US4963556A (en) | 1985-08-16 | 1990-10-16 | Merck & Co., Inc. | Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities |
US4692441A (en) | 1985-08-16 | 1987-09-08 | Merck & Co., Inc. | Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities |
DK179286D0 (en) | 1986-04-18 | 1986-04-18 | Nordisk Gentofte | INSULIN PREPARATION |
US5179079A (en) | 1986-12-16 | 1993-01-12 | Novo Nordisk A/S | Nasal formulation and intranasal administration therewith |
US5690954A (en) | 1987-05-22 | 1997-11-25 | Danbiosyst Uk Limited | Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material |
GB8822857D0 (en) | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
AU639228B2 (en) | 1989-02-17 | 1993-07-22 | Transave, Inc. | Lipid excipient for nasal delivery and topical application |
US5109118A (en) | 1989-07-06 | 1992-04-28 | Yutaka Mizushima | Modified biologically active proteins |
CA2033725C (en) | 1990-01-24 | 2001-05-29 | Folker Pittrof | Pharmaceutical and cosmetic compositions containing a salt of cholanic acid |
GB9007052D0 (en) | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
US5230884A (en) | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
US5416071A (en) | 1991-03-12 | 1995-05-16 | Takeda Chemical Industries, Ltd. | Water-soluble composition for sustained-release containing epo and hyaluronic acid |
ES2136620T3 (en) | 1991-04-19 | 1999-12-01 | Lds Technologies Inc | CONVERTIBLE MICROEMULSION FORMULATIONS. |
US5292489A (en) | 1991-06-24 | 1994-03-08 | Alliedsignal Inc. | Ternary silicon-rare earth nitrides and process for their preparation |
GB9202464D0 (en) | 1992-02-05 | 1992-03-18 | Danbiosyst Uk | Composition for nasal administration |
US5482706A (en) | 1992-04-17 | 1996-01-09 | Takeda Chemical Industries, Ltd. | Transmucosal therapeutic composition |
US5672581A (en) | 1993-01-29 | 1997-09-30 | Aradigm Corporation | Method of administration of insulin |
US5576016A (en) | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
US5506203C1 (en) | 1993-06-24 | 2001-02-06 | Astra Ab | Systemic administration of a therapeutic preparation |
US5747445A (en) | 1993-06-24 | 1998-05-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
IS1796B (en) | 1993-06-24 | 2001-12-31 | Ab Astra | Inhaled polypeptide formulation composition which also contains an enhancer compound |
TW402506B (en) | 1993-06-24 | 2000-08-21 | Astra Ab | Therapeutic preparation for inhalation |
DE4323636A1 (en) | 1993-07-15 | 1995-01-19 | Hoechst Ag | Pharmaceutical preparations from coated, poorly water-soluble pharmaceutical substances for inhalation pharmaceutical forms and processes for their preparation |
US5424289A (en) | 1993-07-30 | 1995-06-13 | Alza Corporation | Solid formulations of therapeutic proteins for gastrointestinal delivery |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
ES2193186T3 (en) | 1993-12-02 | 2003-11-01 | Abbott Lab | DRUG COMPOSITIONS IN AEROSOL FOR USE WITH PROPULSING GASES WITHOUT CFC. |
EP0743851B1 (en) | 1994-02-04 | 2001-06-13 | Scotia Lipidteknik Ab | Lipophilic carrier preparations |
US5447729A (en) | 1994-04-07 | 1995-09-05 | Pharmavene, Inc. | Multilamellar drug delivery systems |
US5451569A (en) | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5898028A (en) | 1997-03-20 | 1999-04-27 | Novo Nordisk A/S | Method for producing powder formulation comprising an insulin |
-
1999
- 1999-08-31 US US09/386,285 patent/US6221378B1/en not_active Expired - Fee Related
-
2000
- 2000-08-25 MX MXPA02002267A patent/MXPA02002267A/en unknown
- 2000-08-25 EP EP00956008A patent/EP1207853A1/en not_active Withdrawn
- 2000-08-25 NZ NZ517313A patent/NZ517313A/en not_active IP Right Cessation
- 2000-08-25 CA CA002382535A patent/CA2382535C/en not_active Expired - Fee Related
- 2000-08-25 JP JP2001519880A patent/JP2003508421A/en active Pending
- 2000-08-25 WO PCT/CA2000/001019 patent/WO2001015666A1/en not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994026302A1 (en) * | 1993-05-12 | 1994-11-24 | Genentech, Inc. | Stable liquid compositions of gamma interferon |
WO1996019197A1 (en) * | 1994-12-22 | 1996-06-27 | Astra Aktiebolag | Aerosol formulations of peptides and proteins |
WO1996036352A1 (en) * | 1995-05-16 | 1996-11-21 | Pankaj Modi | Liquid formulations for proteinic pharmaceuticals comprising at least 2 absorption enhancers |
WO1999040932A1 (en) * | 1998-02-10 | 1999-08-19 | Generex Pharmaceuticals, Inc. | Mixed micellar pharmaceutical delivery system and method of preparation |
WO2000037051A1 (en) * | 1998-12-21 | 2000-06-29 | Generex Pharmaceuticals Inc. | Aerosol formulations for buccal and pulmonary application |
Non-Patent Citations (1)
Title |
---|
YAMAMOTO A ET AL: "Pulmonary absorption enhancement of peptides by absorption enhancers and protease inhibitors", JOURNAL OF CONTROLLED RELEASE, vol. 41, no. 1, 1 August 1996 (1996-08-01), pages 57-67, XP004037571 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003263416C1 (en) * | 1998-12-21 | 2009-03-05 | Generex Pharmaceuticals Inc. | Pharmaceutical compositions for buccal delivery of pain relief medications |
AU2003263416B2 (en) * | 1998-12-21 | 2008-03-06 | Generex Pharmaceuticals Inc. | Pharmaceutical compositions for buccal delivery of pain relief medications |
WO2001072278A3 (en) * | 2000-03-30 | 2002-04-11 | Generex Pharm Inc | Method for administering insulin to the buccal region |
WO2001072278A2 (en) * | 2000-03-30 | 2001-10-04 | Generex Pharmaceuticals Inc. | Method for administering insulin to the buccal region |
EP1452162A1 (en) * | 2001-11-09 | 2004-09-01 | The Nisshin Oil Mills, Ltd. | Gel-form composition |
EP1452162A4 (en) * | 2001-11-09 | 2010-01-06 | Nisshin Oillio Group Ltd | Gel-form composition |
WO2004016244A2 (en) | 2002-08-16 | 2004-02-26 | Generex Pharmaceuticals Inc. | Pharmaceutical compositions for buccal delivery of pain relief medications |
WO2004016244A3 (en) * | 2002-08-16 | 2004-05-21 | Generex Pharm Inc | Pharmaceutical compositions for buccal delivery of pain relief medications |
JPWO2004037859A1 (en) * | 2002-10-11 | 2006-02-23 | 株式会社三和化学研究所 | GLP-1 derivative and transmucosal absorption preparation thereof |
EP1661556A1 (en) * | 2003-08-20 | 2006-05-31 | Ajinomoto Co., Inc. | Medicinal preparation having improved dissolution properties |
EP1661556A4 (en) * | 2003-08-20 | 2010-05-19 | Ajinomoto Kk | Medicinal preparation having improved dissolution properties |
AU2004312043B2 (en) * | 2003-12-26 | 2008-07-31 | Amylin Pharmaceuticals, Inc. | Intranasal administration of glucose-regulating peptides |
WO2005065714A1 (en) * | 2003-12-26 | 2005-07-21 | Nastech Pharmaceutical Company Inc. | Intranasal administration of glucose-regulating peptides |
FR2906140A1 (en) * | 2006-09-22 | 2008-03-28 | Philippe Perovitch | GALENIC FORM FOR TRANSMUCOSUS ADMINISTRATION OF ACTIVE INGREDIENTS |
WO2008035020A3 (en) * | 2006-09-22 | 2009-02-12 | Philippe Perovitch | Galenic form for the trans-mucosal delivery of active ingredients |
US10758479B2 (en) | 2006-09-22 | 2020-09-01 | Philippe Perovitch | Galenical form for the administration of active ingredients by transmucous means |
Also Published As
Publication number | Publication date |
---|---|
CA2382535A1 (en) | 2001-03-08 |
EP1207853A1 (en) | 2002-05-29 |
CA2382535C (en) | 2008-01-22 |
JP2003508421A (en) | 2003-03-04 |
MXPA02002267A (en) | 2002-10-31 |
US6221378B1 (en) | 2001-04-24 |
NZ517313A (en) | 2003-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2382535C (en) | Mixed micellar pharmaceutical delivery system and method of preparation | |
US6231882B1 (en) | Mixed micellar delivery system and method of preparation | |
US6432383B1 (en) | Method for administering insulin | |
US6312665B1 (en) | Aerosol formulations for buccal and pulmonary application | |
US6350458B1 (en) | Mixed micellar drug deliver system and method of preparation | |
AU783431B2 (en) | Pharmaceutical compositions for buccal and pulmonary application | |
US20100203105A1 (en) | Method for administering insulin to the buccal region | |
US6436367B1 (en) | Aerosol formulations for buccal and pulmonary application | |
NZ522524A (en) | Micellar pharmaceutical compositions for buccal and pulmonary application | |
CA2494132C (en) | Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes | |
WO2001072278A2 (en) | Method for administering insulin to the buccal region | |
EP1338272A1 (en) | Aerosol formulations for buccal and pulmonary application comprising chenodeoxycholate or deoxycholate | |
CA2229286C (en) | Mixed micellar delivery system and method of preparation | |
AU763251B2 (en) | Mixed micellar pharmaceutical delivery system and method for preparation | |
AU2002301424B2 (en) | Mixed micellar pharmaceutical delivery system and method of preparation | |
MXPA00007802A (en) | Mixed micellar pharmaceutical delivery system and method of preparation | |
AU2003259466A1 (en) | Methods of administering and enhancing absorption of pharmaceutical agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 517313 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 68143/00 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/002267 Country of ref document: MX Ref document number: 2382535 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000956008 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000956008 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 517313 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 517313 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 68143/00 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000956008 Country of ref document: EP |